Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16652
Title: Health care costs associated with Australian tertiary inflammatory bowel disease care
Austin Authors: Jackson, Belinda;Con, Danny;Ma, Ronald ;Gorelik, Alexandra;Liew, Danny;De Cruz, Peter
Affiliation: Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Melbourne Epicentre, The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
Issue Date: Aug-2017
metadata.dc.date: 2017-05-16
Publication information: Scandinavian Journal of Gastroenterology 2017; 52(8): 851-856
Abstract: Introduction: We aimed to describe the total costs of illness for IBD patients and compare the costs of patients with active disease to those with inactive disease. Materials and methods: Resource use for IBD management was itemized for attributable costs (AUD) among all IBD patients over a 12-month period at an Australian hospital. Results: One hundred and eighty-three patients were included (87 ulcerative colitis (UC); 93 Crohn’s disease (CD); three IBD-unclassified). The median (IQR) annual overall cost was higher in the CD versus UC group ($15,648 versus $5017; p < .001). The difference in cost between CD and UC was influenced by the difference in outpatient costs for CD patients $9602 ($4311–$29,805) versus $4867 ($3220–$7249), p < .001). The cost of treating patients with active disease was $3461 ($1607–$11,771) and was higher in the CD versus the UC group ($6098 ($2168–$16,471) versus $1638 ($1401–$3767); p = .026) and was influenced by inpatient admissions. The cost of treating patients in remission was $2090 ($1552–$12,954) and was higher in the CD versus the UC group [$7977 ($1579–$14,304) versus $1848 ($1508–$6601); p = .236]. Conclusions: There is a discrepancy in costs of inpatient versus outpatient IBD management and treating active disease compared with disease in remission. Proactive care may help prevent disease reaching a severity whereby reactive management of active disease is required.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16652
DOI: 10.1080/00365521.2017.1323117
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/28509590
Type: Journal Article
Subjects: Health care costs
Health economics
Inflammatory bowel disease
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.